

Supporting information

**Non-Enzymatic Protein Templates Amide Bond Formation and  
Provides Catalytic Turnover**

N. Brauckhoff *et al.*

# 1 Methods

## Peptide Synthesis and Characterization

Peptide synthesis was performed on Rink-Amide-MBHA (*p*-methylbenzhydrylamine) resin (Merck Millipore) following standard Fmoc-based solid-phase peptide synthesis (SPPS) protocols.<sup>1</sup> All amino acids were coupled using 4 eq. of Fmoc-protected amino acids according to the initial amine-loading of the resin. The amino acids were mixed with 4 eq. of benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) and 8 eq. of *N,N*-diisopropylethylamine (DIPEA) in *N*-methyl-2-pyrrolidinone (NMP). The resin was incubated with this solution twice for 3 h. Exception was the couplings of fluorescent transfer group to the thiol function of the N-terminal cysteine. Due to lower coupling efficiency, 8 eq. building block, 8 eq. PyBOP and 16 eq. DIPEA were used here. Fmoc-deprotection was performed for 15 min in NMP using 25 % piperidine. After each double-coupling step, unreacted amines were capped for 10 min at RT using Ac<sub>2</sub>O/DIPEA/NMP (1:1:10). For the final *N*-terminal modification, peptides were deprotected as described above and reacted either with capping solution (NMP/Ac<sub>2</sub>O/DIPEA (10:1:1)) for final acetylation or with (2-(2-(Fmoc-amino)ethoxy)ethoxy)acetic acid (Fmoc-NH-PEG-COOH) for spacer coupling. After Fmoc-deprotection, the coupled spacer was *N*-terminally modified with fluorescein isothiocyanate (FITC). Peptides were finally cleaved from the resin using TFA/H<sub>2</sub>O/EDT/TIPS (94:2.5:2.5:1) for 4 h and precipitated with Et<sub>2</sub>O at -20 °C. After final cleavage, the peptides were dissolved in water/acetonitrile (8:2) and purified by reversed-phase HPLC using a Nucleodur C18 reverse-phase column (10 x 125 mm, 110 Å, particle size 5 µm, Macherey-Nagel; solvent A: water + 0.1 % TFA; solvent B: acetonitrile + 0.1 % TFA; flow rate: 6 mL min<sup>-1</sup>). Obtained fractions were frozen in liquid nitrogen and lyophilized with a Heto PowerDry® LL1500 freeze drying system (Thermo). Peptide identity and purity were confirmed by HPLC/ESI-MS (high-performance liquid chromatography/ electrospray ionization mass spectrometry) using an HPLC 1200 system (Agilent Technologies) equipped with a Zorbax Eclipse, XDB-C18 reverse-phase column (4.6 x 150 mm, particle size 5 µm, Agilent; solvent A: water + 0.1 % TFA; solvent B: acetonitrile + 0.1 % TFA; flow rate: 1 mL min<sup>-1</sup>, gradient 2–70 % B in 20 min for peptide A derivatives and 30–70 % B in 20 min for peptide B derivatives). As mass detector a LCQ Advantage Max (Finnigan™) has been used. Analytical data is shown in Supplementary Figures S4 and S5. The peptides were quantified photometrically using a V-550 UV/VIS spectrophotometer (Jasco).

## Protein Expression and Purification of Template Protein (T)

The sequence of the template protein T (for amino acid sequence see Supporting Figures S1) was cloned into a modified pGEX-4T-1 vector (GE Healthcare) and expressed as GST fusion protein in *E. coli* (strain: BL21Gold(DE3)). Terrific Broth (TB) medium supplemented with 150 µg mL<sup>-1</sup> ampicillin was inoculated with *E. coli* overnight pre-culture. This culture was maintained at 37 °C until an OD<sub>600</sub> of 0.8 was reached. Protein expression was initiated by addition of 0.1 mM IPTG and performed overnight at 18 °C. Cells were harvested by centrifugation, resuspended in lysis buffer (50 mM HEPES (pH 7.4), 500 mM NaCl, 2 mM PMSF) and disrupted by microfluidizer. The cell lysate was centrifuged at 70.000 rcf at 4 °C for 1 h to separate cell debris.

GST-T fusion protein was isolated from the supernatant via affinity chromatography (Glutathione Sepharose 4 Fast Flow, GE Healthcare). Following elution, the GST tag was cleaved by addition of Tobacco Etch Virus (TEV) protease.<sup>2</sup> The resulting two protein fragments were separated using size exclusion chromatography (SEC) (HiLoad 16/600 Superdex 75 pg, GE Healthcare, buffer: 25 mM HEPES (pH 7.4), 100 mM NaCl). Remaining GST contamination was removed using a GSTrap HP 1 mL column (GE Healthcare). The purified protein T domain was concentrated via ultrafiltration and stored at -80 °C.

### **Expression and Purification of 2-POI and 2-POI(C1A)**

To express POI (for amino acid sequence see Supporting Figures S1), *E. coli* cells (strain: BL21Gold(DE3)) were transformed with plasmid pET28a(+) containing the corresponding genes. Terrific Broth medium containing 50 µg mL<sup>-1</sup> kanamycin was inoculated with *E. coli* overnight. This culture was maintained at 37 °C until an OD<sub>600</sub> of 0.8 was reached. Protein expression was initiated by addition of 0.1 mM IPTG and performed overnight at 18 °C. Harvested cells were resuspended in lysis buffer (50 mM HEPES (pH 7.4), 500 mM NaCl, 2 mM TCEP, 2 mM PMSF) and disrupted by microfluidizer. The cell lysate was centrifuged at 70.000 rcf at 4 °C for 1 h to separate cell debris. The His-tagged fusion protein was isolated from the supernatant via affinity chromatography (HisTrap FF crude 5 mL, GE Healthcare) and the eluted protein further purified using size exclusion chromatography (HiLoad 16/600 Superdex 75 pg, GE Healthcare, buffer: 25 mM HEPES pH 7.4, 100 mM NaCl, 1 mM TCEP). The purified proteins were concentrated by ultrafiltration and stored at -80 °C.

### **HPLC-based detection of template-mediated transfer reactions**

Peptides **1\*** and **2<sup>#</sup>** were dissolved separately in DMSO to obtain stock solutions with a concentration of 4 mM. For each reaction batch, 10 µM peptide **2<sup>#</sup>** was incubated with 500 µM TCEP in 20 mM sodium phosphate at pH 7.4 for 30 min at 30 °C (Stock-A). Subsequently, 5 µM peptide **1\*** was freshly prepared with and without 5 µM protein template in 20 mM sodium phosphate buffer at pH 7.4 respectively (Stock-A). To start the reaction, 50 µL of Stock-A and 50 µL of Stock-B were combined so that the components were present at final concentrations of 5 µM (**2<sup>#</sup>**) and 2.5 µM (**1\*** and **T**, if applicable) including 250 µM TCEP. The reaction was carried out at 30 °C. The reactions were stopped using 5 µL TFA (5% v/v). To analyze the reaction progress, 100 µL of the reaction solution was used for analytical HPLC (4.6 x 150 mm, particle size 5 µm, Agilent; solvent A: water + 0.1 % TFA; solvent B: acetonitrile + 0.1 % TFA; flow rate: 1 mL min<sup>-1</sup>, gradient 25–70 % B in 20 min). Transfer products **1** and **\*2<sup>#</sup>** were detected via ESI-MS.

### **Fluorescence-based tracking of transfer reactions**

Reactions for fluorescence-based readout were performed in 'transfer buffer' (20 mM sodium phosphate, pH 7.4, 3% HEPES, 500 µM TCEP, 0.01% Tween-20). Peptide stock solutions in DMSO (c(peptide) = 2 mM) were prepared and then accordingly diluted into transfer buffer. For each reaction, 20 µM **2<sup>#</sup>** was incubated with 500 µM TCEP in transfer buffer for 30 min. The concentration of **T** was adjusted to 1 mM in transfer buffer. Finally, 10 µM **1\*** (with specified amount of **T**) was prepared in buffer. To start the reaction, 10 µL of the **2<sup>#</sup>** solution and 10 µL of the **1\*** solution (with or without template **T**) were combined to finally provide 5 µM **1\***, 10 µM **2<sup>#</sup>** and 250 µM TCEP in a total of 20 µL. The concentrations of **T** corresponded to 0, 0.02,

0.05, 0.1, 0.25 and 1 eq. depending on the sample. For referencing, a sample containing exclusively 5  $\mu\text{M}$  FITC-modified 5-aminovaleric acid in 20  $\mu\text{L}$  buffer was included. A microplate reader (Safire2 plate reader, Tecan) with a set excitation wavelength  $\lambda_{\text{ex}}$  of 470 nm and an emission wavelength of 525 nm was used to read the samples (excitation bandwidth 20 nm, emission bandwidth 5 nm). The amplification (gain) was adjusted by the instrument for each measurement (integration time of 2000  $\mu\text{s}$ ). All measurements were performed at 30  $^{\circ}\text{C}$ . For measurements at increased concentrations (Supporting Figure S8), stock solutions were adjusted accordingly.

To determine the fluorescence intensity ( $I$ ), all obtained raw data  $I_{\text{raw}}(X)$  were divided by the corresponding value of the internal standard. For calculation of yields, 0 and 100 % were derived from reference samples and the data accordingly normalized. The turnover number (TON) was calculated based on the transfer yields of template-mediated and -unmediated reactions (Formula 1).<sup>3</sup>

$$TON = [\eta(X \text{ eq. } \mathbf{T}) - \eta(\text{without } \mathbf{T})] \cdot X^{-1}$$

Formula 1: Calculation of the exchange number WZ;  $\eta$  = transfer yield,  $X$  = used equivalents (0 - 1 eq.) of  $\mathbf{T}$ .

### Protein labelling

Initially, a stock solution of **2-POI** and if required of **2-POI(C1A)** was prepared at a concentration of 2  $\mu\text{M}$  in buffer (20 mM sodium phosphate buffer containing 500 mM TCEP, pH 7.4) and incubated for 30 min at RT. In addition, 2  $\mu\text{M}$  of **1\*** was added to 20 mM sodium phosphate buffer with 1 eq.  $\mathbf{T}$ , if necessary. To start the reaction, 50  $\mu\text{L}$  of **2-POI** stock was combined with 50  $\mu\text{L}$  of **1\*** stock to give final concentrations of 1  $\mu\text{M}$  of **1\***, **2-POI**, and, if required,  $\mathbf{T}$ . This reaction mixture was incubated at 30  $^{\circ}\text{C}$ . To stop the reaction and prepare the samples for subsequent SDS-PAGE, 6  $\mu\text{L}$  were combined with 4  $\mu\text{L}$  of SDS sample buffer at given time points and incubated at 95  $^{\circ}\text{C}$  for 5 min. To visualize the labeling of the target protein, SDS-PAGE was performed, loading 10  $\mu\text{L}$  of the respective sample onto the gel. The resulting SDS gel was imaged using a fluorescence reader (Typhoon Trio+ Variable Mode Imager, Amersham) and subsequently stained via Coomassie staining to visualize present protein. For data see Supporting Figure S10 and S11.

### Luciferase activity assay

Initially, stock solutions of **2-POI** and **2-POI(C1A)** were prepared at a concentration of 2  $\mu\text{M}$  in buffer (20 mM sodium phosphate buffer containing 500 mM TCEP, pH 7.4) and incubated for 30 min at RT. In addition, 2  $\mu\text{M}$  of **1\*** was added to 20 mM sodium phosphate buffer with 1 eq.  $\mathbf{T}$ . To start the reaction, 70  $\mu\text{L}$  of **2-POI** or **2-POI (C1A)** stock was combined with 70  $\mu\text{L}$  of **1\*** stock to give final concentrations of 1  $\mu\text{M}$  of **1\***,  $\mathbf{T}$ , as well as **2-POI** or **2-POI (C1A)**. For luciferase readout, 3x 10  $\mu\text{L}$  were collected at the beginning of the reaction and after 120 min, respectively. Each of these aliquots was added to 10  $\mu\text{L}$  Dual-Glo luciferase reagent (Promega) in a 96-well plate and then analyzed using a Safire 2 plate reader (measurement mode: luminescence). For data see supporting Figure S12.

## 2 Supporting Table

**Supporting Table S1:** Synthesized peptides with characteristics (For sequences and analytical data see Supporting Figure S4 and S5).

Peptide	Molecular formula	<i>M</i> g·mol <sup>-1</sup>	<i>m/z</i>	
			calculated	found
<b>f-1a</b>	C <sub>162</sub> H <sub>254</sub> N <sub>49</sub> O <sub>54</sub> P <sub>5</sub>	3815.08	1908.5/1272.7/954.8/764.0	1908.4/1272.7/954.7/764.0
<b>f-1b</b>	C <sub>156</sub> H <sub>240</sub> N <sub>47</sub> O <sub>54</sub> PS	3700.90	1851.5/1234.6/926.2/741.2	1851.0/1234.4/926.2/741.1
<b>f-1</b>	C <sub>156</sub> H <sub>240</sub> N <sub>47</sub> O <sub>53</sub> PS	3684.90	1843.5/1229.3/922.2/738.0	1843.6/1228.9/921.9/738.0
<b>f-2</b>	C <sub>108</sub> H <sub>155</sub> N <sub>23</sub> O <sub>31</sub> S <sub>2</sub>	2335.65	1168.8/779.6/584.9	1168.5/779.3/585.0
<b>1*</b>	C <sub>166</sub> H <sub>256</sub> ClN <sub>49</sub> O <sub>56</sub> PS <sub>2</sub>	3929.21	1965.6/1310.7/983.3/786.8	1965.7/1310.4/983.0/786.7
<b>2#</b>	C <sub>110</sub> H <sub>169</sub> N <sub>28</sub> O <sub>33</sub> S <sub>2</sub>	2486.63	1244.3/829.9/622.7	1245.2/830.4/623.1

### 3 Supporting Figures

#### template (T)

GAMGVRKGWHEHVTQDLRSHLVHKLQVQAI FPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQK  
ELEEKRRSR

#### 2-POI

CGNILPSDIMDFVLKNTLEVLFGQPHMEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYA  
EYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVVFSKKGLO  
KILNVQKLP I IQK I IIMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRT  
ACVRFSHARDPIFGNQ I I PDTAILS VVPFHGFGMFTTLGYLICGFRVVL MYRFEEELFLRSLQDYKIQSALLVPTLFSF  
FAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLP GIRQGYGLTETTSA I LITPEGDDKPGAVGKVV PFFEAKVV  
DLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAE  
ESILLQHPNIFDAGVAGLPDDDAGELPAAVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVV FVDEV PKGLTGKLDARK  
IREILIKAKKGGKIAV

#### 2-POI(C1A)


AGNILPSDIMDFVLKNTLEVLFGQPHMEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYA  
EYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDIYNERELLNSMGISQPTVVVFSKKGLO  
KILNVQKLP I IQK I IIMDSKTDYQGFQSMYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRT  
ACVRFSHARDPIFGNQ I I PDTAILS VVPFHGFGMFTTLGYLICGFRVVL MYRFEEELFLRSLQDYKIQSALLVPTLFSF  
FAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAKRFHLP GIRQGYGLTETTSA I LITPEGDDKPGAVGKVV PFFEAKVV  
DLDTGKTLGVNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVDRLKSLIKYKGYQVAPAE  
ESILLQHPNIFDAGVAGLPDDDAGELPAAVVLEHGKTMTEKEIVDYVASQVTTAKKLRGGVV FVDEV PKGLTGKLDARK  
IREILIKAKKGGKIAV

**Supporting Figure S1:** Protein sequences.

**f-1a** FITC-PEG-DSQKRREILSRRPpSYRKILNDLSSDAP-NH<sub>2</sub>

**f-1b** FITC-PEG-DSQARREILSRRPpSYRAILNDLSSDAP-NH<sub>2</sub>


**f-1** FITC-PEG-DAQARREILSRRPpSYRAILNDLSSDAP-NH<sub>2</sub>



**Supporting Figure S2:** Fluorescently labelled peptides **f-1**, **f-1a**, **f-1b** derived from the cAMP response element-binding protein (CREB) with variations at three positions. Peptide **f-1a** contains the original CREB-derived sequence. Fluorescence polarization assay of these peptides with protein **T** including derived dissociation constants ( $K_d$ ).


**f-2** Ac-GNILPSDIMDFVLKNTK(FITC)-NH<sub>2</sub>

$$K_d = 0.50 \pm 0.05 \text{ nM}$$




**Supporting Figure S3:** Fluorescently labelled peptide **f-2** derived from the mixed-lineage leukemia (MLL) protein. Fluorescence polarization assay of the peptide with protein **T** including derived dissociation constant ( $K_d$ ).


**f-1a** FITC-PEG-DSQKRREILSRRPpSYRKILNDLSSDAP-NH<sub>2</sub> (M: 3815.08 g·mol<sup>-1</sup>)




**f-1b** FITC-PEG-DSQARREILSRRPpSYRAILNDLSSDAP-NH<sub>2</sub> (M: 3700.90 g·mol<sup>-1</sup>)



**f-1** FITC-PEG-DAQARREILSRRPpSYRAILNDLSSDAP-NH<sub>2</sub> (M: 3684.90 g·mol<sup>-1</sup>)




**f-2** Ac-GNILPSDIMDFVLKNTK(FITC)-NH<sub>2</sub> (M: 2335.65 g·mol<sup>-1</sup>)




**Supporting Figure S4:** Characterization of peptides **f-1a**, **f-1b**, **f-1** and **f-2** (for calculated m/z-values see Supporting Table S1).


**1\*** Ac-C[FITC-NH(CH<sub>2</sub>)<sub>4</sub>CO]DAQARREILSRRPpSYRAILNDLSSDAP-NH<sub>2</sub> (M: 3929.21 g·mol<sup>-1</sup>)




**2#** H<sub>2</sub>N-CDDGNILPSDIMDFVLKNTK(DABCYL)-NH<sub>2</sub> (M: 2486.63 g·mol<sup>-1</sup>)



**Supporting Figure S5:** Characterization of peptides **1\*** and **2#** (for calculated m/z-values see Supporting Table S1).




**Supporting Figure S6:** Sequence and MS spectrum of reaction product **1** including calculated and found  $m/z$  values.




B

eq. T	2 h	5 h	( <i>t</i> )
0.05	2.0	3.8	(TON)
0.10	3.1	5.0	(TON)
0.25	2.6	3.6	(TON)

**Supporting Figure S7:** A) Initial rates for fluorescence-based readout (manuscript Figure 3C). B) Corresponding turnover numbers (*TON*) after 2 h and 5 h.




**Supporting Figure S8:** Reaction time-course determined based on fluorescence-based read out for different equivalents of **T** (conditions:  $T = 35\text{ }^{\circ}\text{C}$ , phosphate buffer, pH 7.4,  $c = 50\text{ }\mu\text{M}$  **1\***,  $75\text{ }\mu\text{M}$  **2#**). Turnover numbers (*TON*) after 5 h are provided.




**Supporting Figure S9:** SDS-PAGE gel of **2-POI** expression. Lane 1 = digested cell lysate, lane 2 = supernatant of cell lysate after centrifugation, lane 3 = flow-through of Ni-NTA column purification, lane 4 = wash step of Ni-NTA column purification, lane 5 = sample after digestion using TEV protease and lane 6 = purified **2-POI** after size exclusion chromatography.


2-POI	+	+	+	+	+	+	+	+	+	+
T	+	+	+	+	+	+	+	+	+	-
t / min	0	1	2	5	10	20	30	60	120	120



**Supporting Figure S10:** Full SDS-PAGE gel of manuscript Figure 4B.



**Supporting Figure S11:** SDS-PAGE analysis of time-dependence of labelling reaction with **1\***, **2-POI** or **2-POI(C1A)** and **T** (each  $c = 1\mu\text{M}$ , buffer: 20 mM sodium phosphate, pH 7.4, 500  $\mu\text{M}$  TCEP,  $T = 30\text{ }^\circ\text{C}$ ). Top: fluorescence imaging of gel indicating labelled protein **\*2-POI**, Bottom: Coomassie-stained gel indicative of total protein content.



**Supporting Figure S12:** Luciferase activity of 2-POI and 2-POI(C1A) before and after the labelling reaction ( $t = 120$  min). Errors account for standard deviation derived from three technical replicates.

## References

- 1 W. C. Chan and P. D. White, *Fmoc solid phase peptide synthesis: a practical approach*, Oxford University Press, New York, 2000.
- 2 D. S. Waugh, *Protein Expression Purif.*, 2011, **80**, 283–293.
- 3 M. Boudart, *Chem. Rev*, 1995, **95**, 661–666.